Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens

Elaish, Mohamed; Kang, KiRyong; Xia, Ming; Ali, Ahmed; Shany, Salama A. S.; Wang, Leyi; Jiang, Xi; Lee, C.W.

doi:10.1016/j.vaccine.2015.07.049

Cited by 18 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Novel influenza vaccine designs seek to increase the breadth of heterologous and heterosubtypic cross-protection. One approach is to develop inactivated vaccines that selectively induce broadly neutralizing antibodies that target the conserved regions of viral proteins, such as HA stalk or the ectodomain of M2 protein (M2e) [ 13 , 14 ]. Another approach is to use live attenuated influenza vaccines (LAIV) with capacities to elicit long lasting immunity by stimulating mucosal, cellular, and systemic (IgG) responses that are cross protective against heterologous and heterosubtypic viral infections [ 11 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens

2016

View full text Add to dashboard Cite

Influenza virus mutants that encode C-terminally truncated NS1 proteins (NS1-truncated mutants) are attractive candidates for avian live attenuated influenza vaccine (LAIV) development because they are both attenuated and immunogenic in chickens. We previously showed that a high protective efficacy of NS1-truncated LAIV in chickens corresponds with induction of high levels of type I interferon (IFN) responses in chicken embryonic fibroblast cells. In this study, we investigated the relationship between induction of IFN and IFN-stimulated gene responses in vivo and the immunogenicity and protective efficacy of NS1-truncated LAIV. Our data demonstrates that accelerated antibody induction and protective efficacy of NS1-truncated LAIV correlates well with upregulation of IFN-stimulated genes. Further, through oral administration of recombinant chicken IFN alpha in drinking water, we provide direct evidence that type I IFN can promote rapid induction of adaptive immune responses and protective efficacy of influenza vaccine in chickens.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens

2016

View full text Add to dashboard Cite

show abstract

“…Therefore, the experimental M2e vaccines used in this study were given intranasally. Previous studies comparing intranasal versus subcutaneous administration routes in chickens and mice showed that subcutaneous immunization induced significantly higher Ab levels in the serum compared to intranasal [ 36 , 37 ] but we speculate that local mucosal protection against IAV is perhaps most important compared to systemic protection. Future studies need to directly compare both administration routes using the same products.…”

Section: Discussionmentioning

confidence: 66%

Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model

et al. 2018

View full text Add to dashboard Cite

Swine influenza A viruses (IAV-S) found in North American pigs are diverse and the lack of cross-protection among heterologous strains is a concern. The objective of this study was to compare a commercial inactivated A/H1N1/pdm09 (pH1N1) vaccine and two novel subunit vaccines, using IAV M2 ectodomain (M2e) epitopes as antigens, in a growing pig model. Thirty-nine 2-week-old IAV negative pigs were randomly assigned to five groups and rooms. At 3 weeks of age and again at 5 weeks of age, pigs were vaccinated intranasally with an experimental subunit particle vaccine (NvParticle/M2e) or a subunit complex-based vaccine (NvComplex/M2e) or intramuscularly with a commercial inactivated vaccine (Inact/pH1N1). At 7 weeks of age, the pigs were challenged with pH1N1 virus or sham-inoculated. Necropsy was conducted 5 days post pH1N1 challenge (dpc). At the time of challenge one of the Inact/pH1N1 pigs had seroconverted based on IAV nucleoprotein-based ELISA, Inact/pH1N1 pigs had significantly higher pdm09H1N1 hemagglutination inhibition (HI) titers compared to all other groups, and M2e-specific IgG responses were detected in the NvParticle/M2e and the NvComplex/M2e pigs with significantly higher group means in the NvComplex/M2e group compared to SHAMVAC-NEG pigs. After challenge, nasal IAV RNA shedding was significantly reduced in Inact/pH1N1 pigs compared to all other pH1N1 infected groups and this group also had reduced IAV RNA in oral fluids. The macroscopic lung lesions were characterized by mild-to-severe, multifocal-to-diffuse, cranioventral dark purple consolidated areas typical of IAV infection and were similar for NvParticle/M2e, NvComplex/M2e and SHAMVAC-IAV pigs. Lesions were significantly less severe in the SHAMVAC-NEG and the Inact/pH1N1pigs. Under the conditions of this study, a commercial Inact/pH1N1 specific vaccine effectively protected pigs against homologous challenge as evidenced by reduced clinical signs, virus shedding in nasal secretions and oral fluids and reduced macroscopic and microscopic lesions whereas intranasal vaccination with experimental M2e epitope-based subunit vaccines did not. The results further highlight the importance using IAV-S type specific vaccines in pigs.

show abstract

“…Важно отметить, что у птиц, иммунизированных интраназаль-но, на конъюктиву и микроспреем, значимого титра специфических антител детектировано не было. Кроме того, трехкратное подкожное введение птицам М2е-РР, способно индуци-ровать защиту против вирусов гриппа птиц подтипов H5N2, H7N2 и H6N2 [20]. Обнадежи-вающие данные были получены Равиным Н.В.…”

Section: кандидатные вакцины на основе м2еunclassified

Current Approaches to Universal Vaccine Against Influenza Virus

Булатович

Alekseeva

Саядян

et al. 2016

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Influenza is a seasonal infectious disease widespread across the globe. In Russia the share of influenza and other acute respiratory viral infections account for up to 90% of all infectious diseases. Scientific and reasonable method of influenza prevention is vaccination. However, traditional current influenza vaccines can’t induce protection against various virus strains that differ substantially in terms of their antigenic structure, and thus require periodic updates to its immunogenic components. In addition, there is the risk of a pandemic caused by an entirely new antigen in relation to variants of influenza virus A. Attempts to improve on traditional approaches to vaccination have focused primarily on improving production technologies and to increase immunogenicity of vaccines. Therefore, the urgent task is the creation of vaccines able to induce immune response a broad spectrum against different influenza virus strains and human strains of avian influenza, also can cause disease in humans. Protective effect of universal vaccine should be the induction of integrated immune response, based on the formulation of cross-reactive antibodies and T cells. The development of such universal vaccine could remove the need for periodical strain composition update of existing vaccines and, accor dingly, will be able to give the vaccine manufacturer itself, production planning regardless of epidemic seasons. Currently, the most widely studied antigens as key components of flu vaccines are proteins M2 and NP as well as the hemagglutinin of influenza virus. This review summarizes and lists some data of domestic and foreign research on a universal influenza virus vaccine.

show abstract

Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens

Cited by 18 publications

References 34 publications

Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens

Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens

Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model

Current Approaches to Universal Vaccine Against Influenza Virus

Contact Info

Product

Resources

About